Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | NMBR | P28336 | 3/20 | 0.53 |
| ▸ | TACR1 | P25103 | 1/20 | 0.53 |
| ▸ | TACR3 | P29371 | 1/20 | 0.53 |
| ▸ | BRS3 | P32247 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ECE1 | P42892 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP3 | P08254 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26605057 | 1.00 | CTSL (0.54) | CTSLNMBRTACR1TACR3BRS3 | |
| SCHEMBL29565336 | 0.93 | GHSR (0.58) | BRS3OPRM1OPRD1MMP9MMP8 | |
| SCHEMBL24933037 | 0.91 | CTSL (0.57) | CTSLNMBRTACR1BRS3OPRM1 | |
| SCHEMBL6655016 | 0.91 | CTSL (0.57) | CTSLNMBRTACR1BRS3OPRM1 | |
| SCHEMBL12464196 | 0.88 | OPRM1 (0.60) | CTSLNMBRTACR1TACR3BRS3 | |
| SCHEMBL1305001 | 0.87 | OPRM1 (0.52) | CTSLNMBRTACR1TACR3BRS3 | |
| SCHEMBL12108781 | 0.87 | OPRM1 (0.52) | CTSLNMBRTACR1TACR3BRS3 | |
| SCHEMBL30358212 | 0.86 | ACE (0.54) | CTSLTACR1ALOX15OPRM1OPRD1 | |
| SCHEMBL31238592 | 0.86 | ECE1 (0.64) | ALOX15ECE1ACE | |
| SCHEMBL29564309 | 0.86 | GHSR (0.57) | BRS3OPRM1OPRD1MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257111-A1 | Supramolecular Complex of a Biomolecule | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-08-14 | — | — | US | disclosed |
| EP-4511382-A1 | SUPRAMOLECULAR COMPLEX OF A BIOMOLECULE | Cambridge Enterprise Limited (GB) | 2025-02-26 | — | — | EP | disclosed |
| CN-119233979-A | Supramolecular complexes of biomolecules | 剑桥实业有限公司 | 2024-12-31 | — | — | CN | disclosed |
| WO-2023203201-A1 | SUPRAMOLECULAR COMPLEX OF A BIOMOLECULE | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2023-10-26 | — | — | WO | disclosed |
| US-20070037249-A1 | Molecules that block viral infectivity and methods of use thereof | GOOBAR-LARSSON LAURA | 2007-02-15 | — | — | US | disclosed |
| US-7012129-B2 | Antiviral composition comprising glycine amide | TRIPEP AB (SE) | 2006-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257111-A1 | Supramolecular Complex of a Biomolecule | CCR8, IGFBP1, IGFBP2 | CTSL 462/4885NMBR 3411/4885TACR1 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.